Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer

Annals of Thoracic Surgery

Volumn 92, Issue 5, 2011, Pages 1805-1811

  Shersher, David D ^a   Vercillo, Michael S ^a   Fhied, Cristina ^a   Basu, Sanjib ^a   Rouhi, Omid ^a   Mahon, Brett ^a   Coon, John S ^a   Warren, William H ^a   Faber, L Penfield ^a   Hong, Edward ^a   Bonomi, Philip ^a   Liptay, Michael J ^a   Borgia, Jeffrey A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN BINDING PROTEIN 7; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CIGARETTE SMOKING; CORRELATION ANALYSIS; DIET RESTRICTION; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RACE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-PEPTIDE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 80155194276     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2011.06.058     Document Type: Article

References (31)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. R.S. Herbst, J.V. Heymach, and S.M. Lippman Lung cancer N Engl J Med 359 2008 1367 1380
3. B.K. Edwards, E. Ward, and B.A. Kohler Annual report to the nation on the status of cancer, 19752006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates Cancer 116 2010 544 573
4. W.K. Lam, and D.N. Watkins Lung cancer: future directions Respirology 12 2007 471 477 (Pubitemid 46961832)
5. R. Rami-Porta, J.J. Crowley, and P. Goldstraw The revised TNM staging system for lung cancer Ann Thorac Cardiovasc Surg 15 2009 4 9
6. E.C. Farlow, M.S. Vercillo, and J.S. Coon A multi-analyte serum test for the detection of non-small cell lung cancer Br J Cancer 103 2010 1221 1228
7. J.B. Douglas, D.T. Silverman, M.N. Pollak, Y. Tao, A.S. Soliman, and R.Z. Stolzenberg-Solomon Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial Cancer Epidemiol Biomarkers Prev 19 2010 2298 2306
8. A.G. Renehan, M. Zwahlen, C. Minder, S.T. O'Dwyer, S.M. Shalet, and M. Egger Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis Lancet 363 2004 1346 1353 (Pubitemid 38529873)
9. C. Schairer, D. Hill, and S.R. Sturgeon Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women Int J Cancer 108 2004 773 779 (Pubitemid 38076411)
10. S.A. Rosenzweig, and H.S. Atreya Defining the pathway to insulin-like growth factor system targeting in cancer Biochem Pharmacol 80 2010 1115 1124
11. S.M. Firth, and R.C. Baxter Cellular actions of the insulin-like growth factor binding proteins Endocr Rev 23 2002 824 854 (Pubitemid 35454590)
12. A. Grimberg, and P. Cohen Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis J Cell Physiol 183 2000 1 9 (Pubitemid 30130219)
13. R. Durai, W. Yang, S. Gupta, A.M. Seifalian, and M.C. Winslet The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge Int J Colorectal Dis 20 2005 203 220 (Pubitemid 40552999)
14. R. Dziadziuszko, D.R. Camidge, and F.R. Hirsch The insulin-like growth factor pathway in lung cancer J Thorac Oncol 3 2008 815 818
15. S. Rajaram, D.J. Baylink, and S. Mohan Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions Endocr Rev 18 1997 801 831 (Pubitemid 28009568)
16. D. Lann, and D. LeRoith The role of endocrine insulin-like growth factor-I and insulin in breast cancer J Mammary Gland Biol Neoplasia 13 2008 371 379
17. L. Buckbinder, R. Talbott, and S. Velasco-Miguel Induction of the growth inhibitor IGF-binding protein 3 by p53 Nature 377 1995 646 649
18. A.J. Butt, S.M. Firth, M.A. King, and R.C. Baxter Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells J Biol Chem 275 2000 39174 39181 (Pubitemid 32058934)
19. R. Karmali, M.J. Fidler, and I. Cela Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy J Clin Oncol (Meeting Abstracts) 28 15 suppl 2010 7553
20. J.A. Borgia, S. Basu, and L.P. Faber Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer J Thorac Oncol 4 2009 338 347
21. K. Patel, E.C. Farlow, and A.W. Kim Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers Int J Cancer 29 2011 133 142
22. A. Kaya, A. Ciledag, and B.E. Gulbay The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients Respir Med 98 2004 632 636 (Pubitemid 38949927)
23. A. Neuner, M. Schindel, U. Wildenberg, T. Muley, H. Lahm, and J.R. Fischer Prognostic significance of cytokine modulation in non-small cell lung cancer Int J Cancer 101 2002 287 292 (Pubitemid 34970898)
24. C. Simon, M. Follenius, and G. Brandenberger Postprandial oscillations of plasma glucose, insulin and C-peptide in man Diabetologia 30 1987 769 773 (Pubitemid 17163002)
25. A. Gualberto, M.L. Hixon, and D.D. Karp Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab Br J Cancer 104 2011 68 74
26. A. Sureshbabu, H. Okajima, and D. Yamanaka IGFBP-5 induces epithelial and fibroblast responses consistent with the fibrotic response Biochem Soc Trans 37 2009 882 885
27. A.G. Pallis, L. Serfass, and R. Dziadziusko Targeted therapies in the treatment of advanced/metastatic NSCLC Eur J Cancer 45 2009 2473 2487
28. J. Jassem, C.J. Langer, and D.D. Karp Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 28 15 suppl 2010 7500
29. T.R. Graham, H.E. Zhau, and V.A. Odero-Marah Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells Cancer Res 68 2008 2479 2488 (Pubitemid 351521824)
30. M. Sabbah, S. Emami, and G. Redeuilh Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers Drug Resist Updat 11 2008 123 151
31. R. Sivakumar, H. Koga, K. Selvendiran, M. Maeyama, T. Ueno, and M. Sata Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition Int J Oncol 34 2009 329 338